Skip to content

Emervel for the Correction of Lower Face Wrinkles & Folds

A Multi-Center Study to Evaluate the Perception of Facial Expressions Following Correction of Wrinkles and Folds in the Lower Face Using Emervel® Classic Lidocaine and Emervel® Deep Lidocaine

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02718040
Enrollment
30
Registered
2016-03-24
Start date
2016-04-30
Completion date
2016-08-31
Last updated
2022-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Marionette Lines, Nasolabial Folds, Wrinkles

Brief summary

This study is designed to 1. evaluate the naturalness of facial expressions in motion (2D video images), by treating investigator assessment 2. evaluate naturalness of facial expressions (photographs), by treating investigator assessment 3. evaluate perceived attractiveness and age of subject (2D videos), by treating investigator assessment 4. evaluate aesthetic improvement, by subject and treating investigator assessments 5. evaluate subject satisfaction 6. evaluate nasolabial fold (NLF) severity, by treating investigator assessment 7. evaluate marionette lines (MLs) severity, by treating investigator assessment 8. evaluate dynamic facial strain in animation using 3D digital photogrammetric analysis 9. evaluate all adverse events reported during the study.

Interventions

DEVICEEmervel Classic and/or Deep Treatment Group

Severity of Wrinkle Severity treated by product type: Emervel Classic: Nasolabial Folds (NLFs): Wrinkle Severity Rating Scale (WSRS) = 2/2, 2/3 or 3/3; Marionette Lines (MLs): Wrinkle Assessment Scale (WAS) = 2/2, 2/3 or 3/3 Emervel Deep Nasolabial Folds (NLFs): Wrinkle Severity Rating Scale (WSRS) = 3/3, 3/4 or 4/4; Marionette Lines (MLs): Wrinkle Assessment Scale (WAS) = 3/3, 3/4 or 4/4 Both products may be used in the same subject, but only in different anatomic locations. The same study product should be used within the same wrinkle or fold type (e.g., left and right NLFs treated with the same product)

Sponsors

Galderma R&D
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
40 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

Key Inclusion Criteria: 1. Seeking correction of bilateral NLFs: severe (i.e., bilateral WSRS = 3-4) or moderate (i.e., bilateral WSRS = 2-3) AND bilateral MLs: severe (i.e., WAS = 3-4) or moderate (i.e., WAS = 2-3). 2. Subjects of childbearing potential who agree to use medically accepted methods of contraception during the study and for 30 days following study completion. 3. Intent to undergo optimal correction of bilateral NLFs and MLs. Optimal correction is defined as the best possible aesthetic outcome as agreed to by the treating investigator and subject. Key

Exclusion criteria

1. Subject who presents with a severity of wrinkles or folds that require other treatments, e.g. laser treatment, chemical peeling, to achieve optimal correction. 2. Previous facial surgery, including aesthetic facial surgical therapy, liposuction or tattoo, in the treatment area. 3. Previous tissue augmenting therapy or contouring with permanent or non-permanent filler or fat-injection in the facial area. 4. Previous tissue revitalization treatment with neurotoxin in the facial area within 6 months before treatment. 5. Known/previous allergy or hypersensitivity to any injectable hyaluronic acid (HA) gel. 6. Known/previous allergy or hypersensitivity to local anaesthetics, e.g. lidocaine or other amide-type anaesthetics. 7. Known/previous allergy or hypersensitivity to gram-positive bacterial proteins. 8. Any medical condition that, in the opinion of the treating investigator, would make the subject unsuitable for inclusion (e.g. a chronic, relapsing or hereditary disease that may interfere with the outcome of the study). 9. Other condition preventing the subject from entering the study in the treating investigator's opinion, e.g. subjects not likely to avoid other facial cosmetic treatments, subjects anticipated to be unreliable, unavailable or incapable of understanding the study assessments or having unrealistic expectations of the treatment result.

Design outcomes

Primary

MeasureTime frameDescription
Number of Subjects With Naturalness of Expression in Motion (2D Video)42 daysProportion of subjects having at least maintained naturalness of expression in lower face (naturalness is maintained or enhanced) based on 2D video assessment at Day 42, by treating investigator

Secondary

MeasureTime frameDescription
Number of Subjects With Naturalness of Expression, Attractiveness AND Younger Appearance (2D Video)42 daysProportion of subjects having at least maintained naturalness of expression in the lower face (naturalness is maintained or enhanced) AND attractiveness of the lower face is enhanced AND age of the lower face is younger, based on 2D video assessment at Day 42, by the treating investigator. The is a composite perception assessment; the proportion of subjects must meet all 3 criteria (maintain naturalness, maintain attractiveness, and appear younger in the lower face.
Number of Subjects Reporting Global Improvement (Subject)42 daysAesthetic improvement assessed by subject using the Global Aesthetic Improvement Scale (GAIS). The subject reported GAIS assessment was based on comparing Day 42 to baseline photographs with the following ratings: Very much improved, much improved, somewhat improved, no change, and worse. A clinically significant global improvement was defined as a score of improved, much improved, or very much improved.
Number of Subjects Demonstrating Global Improvement (Treating Investigator)42 daysAesthetic improvement assessed by treating investigator using the Global Aesthetic Improvement Scale (GAIS). The treating investigator reported GAIS assessment was based on comparing Day 42 to baseline photographs with the following ratings: Very much improved, much improved, somewhat improved, no change, and worse. A clinically significant global improvement was defined as a score of improved, much improved, or very much improved.
Number of Subjects Reporting Satisfaction - The Overall Appearance of my Face Looks Natural42 daysProportion of subjects responding with Strongly Agree or Agree. Subject reported satisfaction using a 5-point Likert scale questionnaire. Responses were 1-strongly disagree, 2-disagree, 3-neutral, 4-agree, and 5-strongly agree.
Number of Subjects With Naturalness of Expression (Photographs)42 daysProportion of subjects having at least maintained naturalness of facial expression based on photograph assessment at Day 42, by treating investigator
Wrinkle Severity (Assess MLs) - Proportion of Subjects With Bilateral Improvement of at Least 1 Grade in Wrinkle Severity42 daysWrinkle severity assessed by treating investigator at Day 15/Touch and Day 42 using the Wrinkle Assessment Scale (WAS). Assessments of both MLs were graded according the following responses: 0-no wrinkles, 1-just perceptible wrinkle, 2-shallow wrinkle, 3, moderately deep wrinkle, 4-deep wrinkle, well defined edges, 5-very deep wrinkle, redundant fold. WAS improvement from baseline included 1-grade improvement (reduction in WAS) from baseline.
Mean Change in Dynamic Facial Strain (Stretch) at Day 42 Compared to Baseline - NLF Combined (Global Dynamic Assessment)baseline and 42 daysDynamic strain (stretch) results were analyzed using a Global Dynamic Assessment (GDA).The GDA averages strain (stretch) for the 4 predefined individual expressions, providing a global measure of dynamic strain (stretch), for a specific area of interest (ie, NLF). This value reflects the mean change in dynamic facial stretch at Day 42 compared to Baseline using 3D imaging.
Mean Change in Dynamic Facial Strain (Stretch) at Day 42 Compared to Baseline - ML Combined (Global Dynamic Assessment)baseline and 42 daysDynamic strain (stretch) results were analyzed using a Global Dynamic Assessment (GDA).The GDA averages strain (stretch) for the 4 predefined individual expressions, providing a global measure of dynamic strain (stretch), for a specific area of interest (ie, ML). This value reflects the mean change in dynamic facial stretch at Day 42 compared to Baseline using 3D imaging.
Wrinkle Severity (Assess NLFs) - Proportion of Subjects With Bilateral Improvement of at Least 1 Grade in Wrinkle Severity42 daysWrinkle severity assessed by treating investigator at Day 15/Touch and Day 42 using the Wrinkle Severity Rating Scale (WSRS). Assessments of both NLFs were graded according the following responses: 1-absent, 2-mild, 3-moderate, 4-severe, and 5-extreme. WSRS improvement from baseline included 1-grade improvement (reduction in WSRS) from baseline.

Participant flow

Participants by arm

ArmCount
Emervel Treatment Group
Eligible subjects received bilateral treatment of Nasolabial Folds (NLFs) and Marionette Lines (MLs) with Emervel Classic and/or Emervel Deep Emervel Classic and/or Deep Treatment Group: Severity of Wrinkle Severity treated by product type: Emervel Classic: Nasolabial Folds (NLFs): Wrinkle Severity Rating Scale (WSRS) = 2/2, 2/3 or 3/3; Marionette Lines (MLs): Wrinkle Assessment Scale (WAS) = 2/2, 2/3 or 3/3 Emervel Deep Nasolabial Folds (NLFs): Wrinkle Severity Rating Scale (WSRS) = 3/3, 3/4 or 4/4; Marionette Lines (MLs): Wrinkle Assessment Scale (WAS) = 3/3, 3/4 or 4/4 Both products may be used in the same subject, but only in different anatomic locations. The same study product should be used within the same wrinkle or fold type (e.g., left and right NLFs treated with the same product)
30
Total30

Baseline characteristics

CharacteristicEmervel Treatment Group
Age, Continuous55.0 Years
STANDARD_DEVIATION 6.01
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
0 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
30 Participants
Region of Enrollment
Canada
30 Participants
Sex: Female, Male
Female
30 Participants
Sex: Female, Male
Male
0 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 30
other
Total, other adverse events
0 / 30
serious
Total, serious adverse events
0 / 30

Outcome results

Primary

Number of Subjects With Naturalness of Expression in Motion (2D Video)

Proportion of subjects having at least maintained naturalness of expression in lower face (naturalness is maintained or enhanced) based on 2D video assessment at Day 42, by treating investigator

Time frame: 42 days

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Emervel Treatment GroupNumber of Subjects With Naturalness of Expression in Motion (2D Video)30 Participants
Secondary

Mean Change in Dynamic Facial Strain (Stretch) at Day 42 Compared to Baseline - ML Combined (Global Dynamic Assessment)

Dynamic strain (stretch) results were analyzed using a Global Dynamic Assessment (GDA).The GDA averages strain (stretch) for the 4 predefined individual expressions, providing a global measure of dynamic strain (stretch), for a specific area of interest (ie, ML). This value reflects the mean change in dynamic facial stretch at Day 42 compared to Baseline using 3D imaging.

Time frame: baseline and 42 days

ArmMeasureValue (MEAN)Dispersion
Emervel Treatment GroupMean Change in Dynamic Facial Strain (Stretch) at Day 42 Compared to Baseline - ML Combined (Global Dynamic Assessment)-2.209 Percent of StretchStandard Deviation 2.8716
Secondary

Mean Change in Dynamic Facial Strain (Stretch) at Day 42 Compared to Baseline - NLF Combined (Global Dynamic Assessment)

Dynamic strain (stretch) results were analyzed using a Global Dynamic Assessment (GDA).The GDA averages strain (stretch) for the 4 predefined individual expressions, providing a global measure of dynamic strain (stretch), for a specific area of interest (ie, NLF). This value reflects the mean change in dynamic facial stretch at Day 42 compared to Baseline using 3D imaging.

Time frame: baseline and 42 days

ArmMeasureValue (MEAN)Dispersion
Emervel Treatment GroupMean Change in Dynamic Facial Strain (Stretch) at Day 42 Compared to Baseline - NLF Combined (Global Dynamic Assessment)-1.836 Percent of StretchStandard Deviation 2.1025
Secondary

Number of Subjects Demonstrating Global Improvement (Treating Investigator)

Aesthetic improvement assessed by treating investigator using the Global Aesthetic Improvement Scale (GAIS). The treating investigator reported GAIS assessment was based on comparing Day 42 to baseline photographs with the following ratings: Very much improved, much improved, somewhat improved, no change, and worse. A clinically significant global improvement was defined as a score of improved, much improved, or very much improved.

Time frame: 42 days

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Emervel Treatment GroupNumber of Subjects Demonstrating Global Improvement (Treating Investigator)30 Participants
Secondary

Number of Subjects Reporting Global Improvement (Subject)

Aesthetic improvement assessed by subject using the Global Aesthetic Improvement Scale (GAIS). The subject reported GAIS assessment was based on comparing Day 42 to baseline photographs with the following ratings: Very much improved, much improved, somewhat improved, no change, and worse. A clinically significant global improvement was defined as a score of improved, much improved, or very much improved.

Time frame: 42 days

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Emervel Treatment GroupNumber of Subjects Reporting Global Improvement (Subject)30 Participants
Secondary

Number of Subjects Reporting Satisfaction - The Overall Appearance of my Face Looks Natural

Proportion of subjects responding with Strongly Agree or Agree. Subject reported satisfaction using a 5-point Likert scale questionnaire. Responses were 1-strongly disagree, 2-disagree, 3-neutral, 4-agree, and 5-strongly agree.

Time frame: 42 days

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Emervel Treatment GroupNumber of Subjects Reporting Satisfaction - The Overall Appearance of my Face Looks Natural30 Participants
Secondary

Number of Subjects With Naturalness of Expression, Attractiveness AND Younger Appearance (2D Video)

Proportion of subjects having at least maintained naturalness of expression in the lower face (naturalness is maintained or enhanced) AND attractiveness of the lower face is enhanced AND age of the lower face is younger, based on 2D video assessment at Day 42, by the treating investigator. The is a composite perception assessment; the proportion of subjects must meet all 3 criteria (maintain naturalness, maintain attractiveness, and appear younger in the lower face.

Time frame: 42 days

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Emervel Treatment GroupNumber of Subjects With Naturalness of Expression, Attractiveness AND Younger Appearance (2D Video)25 Participants
Secondary

Number of Subjects With Naturalness of Expression (Photographs)

Proportion of subjects having at least maintained naturalness of facial expression based on photograph assessment at Day 42, by treating investigator

Time frame: 42 days

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Emervel Treatment GroupNumber of Subjects With Naturalness of Expression (Photographs)28 Participants
Secondary

Wrinkle Severity (Assess MLs) - Proportion of Subjects With Bilateral Improvement of at Least 1 Grade in Wrinkle Severity

Wrinkle severity assessed by treating investigator at Day 15/Touch and Day 42 using the Wrinkle Assessment Scale (WAS). Assessments of both MLs were graded according the following responses: 0-no wrinkles, 1-just perceptible wrinkle, 2-shallow wrinkle, 3, moderately deep wrinkle, 4-deep wrinkle, well defined edges, 5-very deep wrinkle, redundant fold. WAS improvement from baseline included 1-grade improvement (reduction in WAS) from baseline.

Time frame: 42 days

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Emervel Treatment GroupWrinkle Severity (Assess MLs) - Proportion of Subjects With Bilateral Improvement of at Least 1 Grade in Wrinkle Severity30 Participants
Secondary

Wrinkle Severity (Assess NLFs) - Proportion of Subjects With Bilateral Improvement of at Least 1 Grade in Wrinkle Severity

Wrinkle severity assessed by treating investigator at Day 15/Touch and Day 42 using the Wrinkle Severity Rating Scale (WSRS). Assessments of both NLFs were graded according the following responses: 1-absent, 2-mild, 3-moderate, 4-severe, and 5-extreme. WSRS improvement from baseline included 1-grade improvement (reduction in WSRS) from baseline.

Time frame: 42 days

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Emervel Treatment GroupWrinkle Severity (Assess NLFs) - Proportion of Subjects With Bilateral Improvement of at Least 1 Grade in Wrinkle Severity30 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026